Rapid Novor Protein Sequencing and Epitope Mapping Analysis Grant

Grants available to research scientists to facilitate access to and usage of antibody protein sequencing technology. 

Rapid Novor is a privately owned facility in Canada that provides antibody protein sequencing technology, specialising in the field of mass spectrometry-based proteomics. The company’s vision is to elevate human health by decoding immunity.

Rapid Novor is offering a Protein Sequencing and Epitope Mapping Analysis Grant. The purpose of this grant is to support academic scientists by providing in-kind access to Rapid Novor’s protein sequencing and epitope mapping (HDX-MS) services. The services are as follows:

• Protein sequencing with mass spectrometry (MS) is a powerful analytical technique used to determine the amino acid sequences of proteins without requiring prior genetic information.
• HDX-MS is a mass spectrometry-based technique used to examine protein-protein interactions, including antibody-antigen interactions, protein conformational changes, multi-protein complexes, and small molecule interactions with proteins. 

Through access to these technologies, scientists can accelerate discovery, validate experimental results and deepen understanding of complex biological systems to drive transformative scientific breakthroughs.

The grant will be awarded to two projects: one which requires protein sequencing technology and another which requires HDX-MS services. Projects must clearly demonstrate the need for protein sequencing or HDX-MS to address specific research questions in fields such as immunology, oncology, structural biology or a related area. Grants can be awarded to the same individual or two different recipients.